Paolo is a growth factor expert and the CSO of Agomab. He spent several years conducting research at the National Cancer Institute, National Institutes of Health in Bethesda, Maryland, in the laboratory that discovered that MET is the HGF receptor in the early 1990s. Since he returned to Italy, he has been directing a translational medicine lab at the University of Torino Medical School, exploring new therapeutic strategies in both oncology and regenerative medicine. In collaboration with argenx, Paolo’s team generated a set of MET-agonistic, HGF-mimetic antibodies with powerful anti-fibrotic and pro-regenerative potential. This discovery led to the foundation of Agomab. Paolo holds a MSc in Biology from the University of Milano, a PhD in Cell Sciences and Technologies from the University of Torino and a Clinical Pathology Specialty Diploma from the University of Torino.